The impact of new guidelines for glucose tolerance testing on clinical practice and laboratory services

CMAJ. Canadian Medical Association Journal

Volumn 171, Issue 9, 2004, Pages 1067-1069

  Lyon, Andrew W ^a,c   Larsen, Erik T ^a,c   Edwards, Alun L ^b,d  

^a UNIVERSITY OF CALGARY   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c CALGARY LABORATORY SERVICES   (Canada)

^d Diabetes Education Centre   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

CANADA; CLINICAL PRACTICE; DIABETES MELLITUS; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; GLUCOSE TOLERANCE TEST; HUMAN; IMPAIRED GLUCOSE TOLERANCE; LABORATORY; NOTE; PRACTICE GUIDELINE;

EID: 7944223788     PISSN: 08203946     EISSN: None     Source Type: Journal    
DOI: 10.1503/cmaj.1040138     Document Type: Note

References (24)

1. Canadian Diabetes Association 2003 clinical practice guidelines for the prevention and management of diabetes in Canada. Can J Diabetes 2003;27(Suppl 2):S10-3.
2. Meltzer S, Leiter L, Daneman D, Gerstein HC, Lau D, Ludwig S, et al. 1998 clinical practice guidelines for the management of diabetes in Canada. CMAJ 1998;159(8 Suppl):S1-29.
3. Diabetes in Canada. 2nd ed. Ottawa: Health Canada; updated 2003 Jan 17. Available: www.hc-sc.gc.ca/pphb-dgspsp/publicat/dic-dac2/english/01cover_e .html (accessed 2004 Sep 16).
4. Kernohan AFB, Perry CG, Small M. Clinical impact of the new criteria for the diagnosis of diabetes mellitus. Clin Chem Lab Med 2003;41:1239-45.
5. Marshall KG. The folly of population screening for type 2 diabetes [editorial]. CMAJ 1999;160(11):1592-3.
6. Gerstein HC, Meltzer S. Preventive medicine in people at high risk for chronic disease: the value of identifying and treating diabetes [editorial]. CMAJ 1999;160(11):1593-4, discussion 1595-6.
7. Young TK, Mustard CA. Undiagnosed diabetes? Does it matter? CMAJ 2001;164(1):24-8.
8. Tuomilehto J, Lindstrom J, Eriksson JG, Valle TT, Hamalainen H, Ilanne-Parikka P, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle amongst individuals with impaired glucose tolerance. N Engl J Med 2001;344 (18):1343-50.
9. Knowler WC, Barrett-Connor E, Fowler SE, Hamman RF, Lachin JM, Walker EA, et al; Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002;346(6):393-403.
10. Ganda OP, Day JL, Soeldner JS, Connon JJ, Gleason RE. Reproducibility and comparative analysis of repeated intravenous and oral glucose tolerance tests. Diabetes 1978;27:715-25.
11. Ko GT, Chan JC, Woo J, Lau E, Yeung VT, Chow CC, et al. The reproducibility and usefulness of the oral glucose tolerance test in screening for diabetes and other cardiovascular risk factors. Ann Clin Biochem 1998;35:62-7.
12. Shaw JE, de Courten M, Boyko EJ, Zimmet PZ. Impact of new diagnostic criteria for diabetes on different populations. Diabetes Care 1999;22:762-6.
13. Will new diagnostic criteria for diabetes mellitus change phenotype of patients with diabetes? Reanalysis of European epidemiological data. DECODE Study Group on behalf of the European Diabetes Epidemiology Study Group. BMJ 1998;317(7155):371-5.
14. Sievenpiper JL, Leiter LA, Vuksan V. Intrasubject coefficient-of- variation corresponds to diagnostic reproducibility in diabetes screening. Can J Diabetes 2002;26:105-12.
15. Schousboe K, Henriksen JE, Kyvik KO, Sorensen TI, Hyltoft Petersen P. Reproducibility of S-insulin and B-glucose responses in two identical oral glucose tolerance tests. Scand J Clin Lab Invest 2002;62(8):623-30.
16. Anand SS, Razak F, Vuksan V, Gerstein HC, Malmberg K, Yi Q, et al. Diagnostic strategies to detect glucose intolerance in a multiethnic population. Diabetes Care 2003;26:290-6.
17. Jorgensen LG, Stahl M, Brandslund I, Hyltoft Petersen P, Borch-Johnsen K, de Fine Olivarius N. Plasma glucose reference interval in a low-risk population. 2. Impact of the new WHO and ADA recommendations on the diagnosis of diabetes mellitus. Scand J Clin Lab Invest 2001;61(3):181-90.
18. Van Walraven C. Practice guidelines and practicing physicians - Who's guiding whom? [editorial]. Clin Chem 2002;48:9-10.
19. Genest J, Frolich J, Fodor J, McPherson R (the Working Group on Hypercholesterolemia and Other Dyslipidemias). Recommendations for the management of dyslipidemia and the prevention of cardiovascular disease: 2003 update. CM47 2003;168(9):Online-1 to Online-10. Available: www.cmaj.ca/cgi/ content/full/169/9/921/DC1 (accessed 2004 Sep 16).
20. Stevens RJ, Kothari V, Adler AI, Straften IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56) [published erratum appears in Clin Sci (Lond) 2002;102(6):679]. Clin Sci (Lond) 2001;101(6): 671-9.
21. Stevens RJ, Kothari V, Adler AI, Straften IM; United Kingdom Prospective Diabetes Study (UKPDS) Group. The UKPDS risk engine: a model for the risk of coronary heart disease in type II diabetes (UKPDS 56) [published erratum appears in Clin Sci (Lond) 2002;102(6):679]. Clin Sci (Lond) 2001;101(6): 671-9.
22. Stern MP, Williams K, Haffner SM. Identification of persons at high risk for type 2 diabetes mellitus: Do we need the oral glucose tolerance test? Ann Intern Med 2002;136:575-81.
23. Engelau MM, Narayan KMV, Vinicor F. Identifying the target population for primary prevention: the trade-offs. Diabetes Care 2002;25:2098-9.
24. Saydah SH, Byrd-Holt D, Harris MI. Projected impact of implementing the results of the diabetes prevention program in the US population. Diabetes Care 2002;25:1940-5.